EE173 Cost-Effectiveness of Risdiplam for Patients with Types 1 - 3 Spinal Muscular Atrophy (SMA) in Francecost-Effectiveness of Risdiplam for Patients with Types 1 - 3 Spinal Muscular Atrophy (SMA) in France
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.423
https://www.valueinhealthjournal.com/article/S1098-3015(22)02627-4/fulltext
Title :
EE173 Cost-Effectiveness of Risdiplam for Patients with Types 1 - 3 Spinal Muscular Atrophy (SMA) in Francecost-Effectiveness of Risdiplam for Patients with Types 1 - 3 Spinal Muscular Atrophy (SMA) in France
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02627-4&doi=10.1016/j.jval.2022.09.423
First page :
Section Title :
Open access? :
No
Section Order :
12233